Sleep is universal on both the species and the individual level. Though there have been reports of individuals, both in humans and other species, who need almost no sleep, a truly sleepless individual has never been identified.

LONDON – Medalliance SA says its sirolimus-coated balloon catheter for the treatment of coronary artery disease will be in U.S. patients this time next year, after the device was awarded a U.S. FDA breakthrough device designation. The device, called Selution, uses biodegradable polymer micro reservoirs to hold sirolimus, enabling the anti-restenotic drug to be released in a controlled and sustained way.

Lexington, Mass.-based T2 Biosystems Inc. won breakthrough device designation for the T2resistance panel, which can detect 13 resistance genes from both gram-positive and gram-negative pathogens. Of note, it can detect those pathogens from a single patient blood sample, without the wait for a blood culture.